Just been scrolling through some biotech plays and honestly, there's a few that caught my eye. Most people sleep on these kinds of stocks but if you're into the higher risk stuff, worth paying attention to.

So like, Adicet Bio is working on gamma delta T-cells for cancer and autoimmune stuff. The market for this is supposed to explode from like $2.83B to $32B by 2030. Stock's got unanimous analyst love and they're calling like 341% upside. That's wild for a company under $200M market cap.

Then there's Stoke Therapeutics focusing on RNA medicines - they've got this platform called TANGO. They're looking at Dravet syndrome which is brutal, honestly. RNA therapeutics market is growing too. The thing is their financials are rough but they've got crazy cash reserves. Analysts still rate it strong buy though.

Actinium is doing targeted radiotherapy for cancer patients who've failed other treatments. Market for radiation oncology could hit $19.2B by 2032. Down 31% over a year but unanimous strong buy rating from analysts.

Clearside Biomedical has this unique FDA-approved delivery method for retinal diseases - first of its kind in the suprachoroidal space. Stock's been flat but the clinical wins are real. Analysts see like $5.67 upside.

Karyopharm's the SINE technology leader for cancer. Three-year revenue growth at 42.7% is legit. They're calling $10 high-side price target.

Outlook Therapeutics is rougher - down 63% in a year - but they're working on an FDA-approved bevacizumab formulation for wet AMD. No revenue since 2020 but analysts still bullish.

Cara Therapeutics focuses on pruritus treatment. Launched the first approved product for dialysis patients with severe itching. Unanimous strong buy, $7.13 average target.

Obviously biotech penny stocks are volatile as hell and most fail. But if you're doing your homework and looking at analyst consensus, these have some interesting setups. Just be ready for the swings.